CY1122553T1 - Μεθοδοι παρασκευης κυτταροτοξικων παραγωγων βενζοδιαζεπινης - Google Patents

Μεθοδοι παρασκευης κυτταροτοξικων παραγωγων βενζοδιαζεπινης

Info

Publication number
CY1122553T1
CY1122553T1 CY20191101364T CY191101364T CY1122553T1 CY 1122553 T1 CY1122553 T1 CY 1122553T1 CY 20191101364 T CY20191101364 T CY 20191101364T CY 191101364 T CY191101364 T CY 191101364T CY 1122553 T1 CY1122553 T1 CY 1122553T1
Authority
CY
Cyprus
Prior art keywords
methods
benzodiazepine derivatives
cytotoxic benzodiazepine
preparing cytotoxic
preparing
Prior art date
Application number
CY20191101364T
Other languages
English (en)
Inventor
Baudouin GÉRARD
Manami Shizuka
Michael Louis Miller
Richard A. Silva
Original Assignee
Immunogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen, Inc. filed Critical Immunogen, Inc.
Publication of CY1122553T1 publication Critical patent/CY1122553T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)

Abstract

Η εφεύρεση αφορά νέες μεθόδους για την παρασκευή ενώσεων διμερούς ινδολινοβενζοδιαζεπίνης και των συνθετικών τους προδρόμων.
CY20191101364T 2015-07-21 2019-12-30 Μεθοδοι παρασκευης κυτταροτοξικων παραγωγων βενζοδιαζεπινης CY1122553T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195023P 2015-07-21 2015-07-21
US201662327973P 2016-04-26 2016-04-26
PCT/US2016/043406 WO2017015496A1 (en) 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives

Publications (1)

Publication Number Publication Date
CY1122553T1 true CY1122553T1 (el) 2021-01-27

Family

ID=56557925

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191101364T CY1122553T1 (el) 2015-07-21 2019-12-30 Μεθοδοι παρασκευης κυτταροτοξικων παραγωγων βενζοδιαζεπινης
CY20201100899T CY1123390T1 (el) 2015-07-21 2020-09-23 Μεθοδοι παρασκευης κυτταροτοξικων παραγωγων βενζοδιαζεπινων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100899T CY1123390T1 (el) 2015-07-21 2020-09-23 Μεθοδοι παρασκευης κυτταροτοξικων παραγωγων βενζοδιαζεπινων

Country Status (22)

Country Link
US (11) US9890179B2 (el)
EP (7) EP3325482B1 (el)
JP (8) JP6858745B2 (el)
KR (5) KR20240055903A (el)
CN (5) CN113004288A (el)
AU (7) AU2016297608B2 (el)
CA (4) CA2992082A1 (el)
CY (2) CY1122553T1 (el)
DK (2) DK3325483T3 (el)
ES (4) ES2933376T3 (el)
HK (3) HK1252322A1 (el)
HR (1) HRP20201479T1 (el)
HU (1) HUE051541T2 (el)
IL (10) IL286788B2 (el)
LT (2) LT3325482T (el)
PL (2) PL3325482T3 (el)
PT (2) PT3325482T (el)
RS (2) RS59806B1 (el)
RU (3) RU2727151C2 (el)
SG (2) SG10202106529XA (el)
SI (2) SI3325483T1 (el)
WO (3) WO2017015496A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113004288A (zh) * 2015-07-21 2021-06-22 伊缪诺金公司 制备细胞毒性苯并二氮杂䓬衍生物的方法
KR102609698B1 (ko) 2016-03-22 2023-12-04 에베 그룹 에. 탈너 게엠베하 기판을 결합하기 위한 방법 및 장치
WO2018075692A2 (en) 2016-10-19 2018-04-26 Invenra Inc. Antibody constructs
EA201991204A1 (ru) 2016-12-22 2019-12-30 Университа Дельи Студи Манья Греча Катандзаро Моноклональное антитело против уникального сиалогликозилированного опухолеассоциированного эпитопа cd43
IL287405B (en) * 2017-01-25 2022-07-01 Immunogen Inc Methods for preparing cytotoxic benzodiazepine derivatives
AU2019283314A1 (en) 2018-06-05 2021-01-07 GammaDelta Therapeutics Limited BTNL3/8 targeting constructs for delivery of payloads to the gastrointestinal system
US10913713B2 (en) * 2018-11-12 2021-02-09 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
AU2019379104A1 (en) 2018-11-12 2021-06-03 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
CN113661172A (zh) * 2019-03-29 2021-11-16 伊缪诺金公司 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860600A (en) 1972-07-10 1975-01-14 Sterling Drug Inc Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines
US3763183A (en) 1972-07-10 1973-10-02 Sterling Drug Inc 1,2,3,10,11,11a-hexahydro-5h-pyrrolo (2,1-c)(1,4)benzodiazepines
US4678784A (en) 1984-04-11 1987-07-07 Mcneilab, Inc. Method for the treatment of LHRH diseases and conditions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9205051D0 (en) 1992-03-09 1992-04-22 Cancer Res Campaign Tech Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
DE69925133T2 (de) 1998-08-27 2006-01-19 Spirogen Ltd., Ryde Pyrrolobenzodiazepine
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
ATE349438T1 (de) 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
US6548042B2 (en) * 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
UA75093C2 (en) * 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
MXPA05001390A (es) 2002-08-02 2005-07-29 Immunogen Inc Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico.
AU2003259163B2 (en) 2002-08-16 2008-07-03 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
CA2520898C (en) 2003-03-31 2009-10-20 Council Of Scientific And Industrial Research Non-cross-linking pyrrolo(2,1-c)(1,4)benzodiazepines as potential antitumour agents and process thereof
EP1608663B1 (en) 2003-03-31 2008-11-05 Council of Scientific and Industrial Research Pyrrolo (2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
RU2338747C2 (ru) 2003-03-31 2008-11-20 Каунсил Оф Сайентифик Энд Индастриал Рисерч ДИМЕРЫ ПИРРОЛО [2, 1-c][1, 4] БЕНЗОДИАЗЕПИНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
RU2314309C2 (ru) 2003-03-31 2008-01-10 Каунсил Оф Сайентифик Энд Индастриал Рисерч Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2005040170A2 (en) 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
AU2003300718A1 (en) 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Process for preparing pyrrolo(2, 1-c) (1, 4) benzodiazepine hybrids
GB0404578D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
PT2270010E (pt) * 2004-03-01 2012-03-12 Spirogen Ltd Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
GB0412492D0 (en) * 2004-06-04 2004-07-07 Sterix Ltd Compound
GB0508084D0 (en) * 2005-04-21 2005-06-01 Spirogen Ltd Pyrrolobenzodiazepines
GB2439881C (en) 2005-04-21 2011-08-10 Spirogen Ltd Pyrrolobenzodiazepines
US8637664B2 (en) 2005-10-05 2014-01-28 Spirogen Sarl Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
RU2467007C2 (ru) * 2005-12-21 2012-11-20 Эбботт Лэборетриз Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv
RS52060B (en) 2006-01-25 2012-04-30 Sanofi CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES
DE112007000079B4 (de) 2006-02-13 2015-08-13 Council Of Scientific & Industrial Research Neuartige Bis-Pyrrolo[2,1-c][1,4]benzodiazepin-anthrachinon Konjugate und ein Verfahren zu deren Herstellung
TWI523864B (zh) 2006-05-30 2016-03-01 建南德克公司 抗體及免疫接合物及其用途
PT2019104E (pt) 2007-07-19 2013-12-03 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica
JP5404624B2 (ja) 2007-08-01 2014-02-05 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ 選択的な抗腫瘍薬として有用なピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−グリコシドプロドラッグ
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
KR101764081B1 (ko) 2008-04-30 2017-08-01 이뮤노젠 아이엔씨 가교제 및 그 용도
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
GB0822260D0 (en) 2008-12-05 2009-01-14 Merten Christoph Assay
EP2383263B1 (en) * 2008-12-30 2014-04-16 Industry-academic Cooperation Foundation, Chosun University Novel thiazolidinedione derivative and use thereof
MX2011008328A (es) 2009-02-05 2011-11-04 Immunogen Inc Derivados novedosos de benzodiacepina.
IN2012DN02780A (el) 2009-10-06 2015-09-18 Immunogen Inc
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
CN102666480B (zh) 2009-12-08 2014-04-09 国立大学法人岐阜大学 芳香族化合物、低聚核苷酸衍生物合成用修饰载体、低聚核苷酸衍生物及低聚核苷酸构建物
US8962279B2 (en) * 2009-12-30 2015-02-24 Intel Corporation Solid-phase chelators and electronic biosensors
ES2730763T3 (es) * 2010-02-11 2019-11-12 Celgene Corp Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos
KR101637138B1 (ko) 2010-02-24 2016-07-06 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
EP2789622B1 (en) 2010-04-15 2017-03-01 MedImmune Limited Pyrrolobenzodiazepines used to treat proliferative diseases
EA024118B1 (ru) * 2010-04-15 2016-08-31 Сиэтл Дженетикс, Инк. Конъюгаты пирролбензодиазепина направленного действия
EP2528625B1 (en) 2010-04-15 2013-07-10 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
DK2675479T3 (en) 2011-02-15 2016-04-11 Immunogen Inc cytotoxic benzodiazepine
CN102234253B (zh) * 2011-06-02 2013-07-03 重庆莱美药业股份有限公司 一种制备非布索坦中间体的方法
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
WO2015051045A2 (en) * 2013-10-04 2015-04-09 Novartis Ag 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE
CN104628772A (zh) * 2013-11-07 2015-05-20 四川恒康发展有限责任公司 一种抗肿瘤前药及其激活剂、组合物和应用
CN103664896B (zh) * 2013-11-25 2016-03-02 济南精合医药科技有限公司 一种抗肿瘤分子靶向药物克里唑替尼的合成工艺方法
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
CA2957964A1 (en) * 2014-09-03 2016-03-10 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
SG11201701455SA (en) 2014-09-03 2017-03-30 Immunogen Inc Cytotoxic benzodiazepine derivatives
CN113004288A (zh) 2015-07-21 2021-06-22 伊缪诺金公司 制备细胞毒性苯并二氮杂䓬衍生物的方法
JP2019501139A (ja) * 2015-11-25 2019-01-17 イミュノジェン・インコーポレーテッド 医薬製剤及びその使用

Also Published As

Publication number Publication date
AU2023201339A1 (en) 2023-04-06
ES2764548T3 (es) 2020-06-03
JP2023166434A (ja) 2023-11-21
EP3325483A1 (en) 2018-05-30
JP2022046542A (ja) 2022-03-23
IL286788A (en) 2021-10-31
US20210171547A1 (en) 2021-06-10
IL256861B (en) 2020-08-31
SG10202009354SA (en) 2020-11-27
PT3325482T (pt) 2020-09-24
KR20240055903A (ko) 2024-04-29
RS59806B1 (sr) 2020-02-28
AU2021202403B2 (en) 2022-12-08
IL276631A (en) 2020-09-30
WO2017015502A1 (en) 2017-01-26
CN113004288A (zh) 2021-06-22
CY1123390T1 (el) 2022-03-24
JP7334228B2 (ja) 2023-08-28
CA3227588A1 (en) 2017-01-26
US10370389B2 (en) 2019-08-06
US20200017526A1 (en) 2020-01-16
US9890179B2 (en) 2018-02-13
EP4163284A1 (en) 2023-04-12
KR20180026741A (ko) 2018-03-13
KR20180038461A (ko) 2018-04-16
AU2016297607A1 (en) 2018-02-08
JP7337114B2 (ja) 2023-09-01
CA2992082A1 (en) 2017-01-26
IL256860A (en) 2018-03-29
IL305279A (en) 2023-10-01
KR20240055894A (ko) 2024-04-29
DK3325482T3 (da) 2020-09-28
IL276630B (en) 2021-06-30
US20170050986A1 (en) 2017-02-23
EP3325483B1 (en) 2019-10-02
AU2016297087B2 (en) 2021-02-18
ES2959741T3 (es) 2024-02-28
DK3325483T3 (da) 2020-01-20
HUE051541T2 (hu) 2021-03-01
IL294651B1 (en) 2023-10-01
EP3653628A1 (en) 2020-05-20
RU2018105752A (ru) 2019-08-21
IL286788B2 (en) 2024-01-01
JP2021100959A (ja) 2021-07-08
US20190389883A1 (en) 2019-12-26
HK1252321A1 (zh) 2019-05-24
IL276630A (en) 2020-09-30
JP6787995B2 (ja) 2020-11-18
ES2933376T3 (es) 2023-02-06
EP3778602A1 (en) 2021-02-17
CN108026103B (zh) 2021-04-16
PT3325483T (pt) 2020-01-15
AU2021203148B2 (en) 2023-01-12
WO2017015495A1 (en) 2017-01-26
AU2021203148A1 (en) 2021-06-10
IL256861A (en) 2018-03-29
US9873708B2 (en) 2018-01-23
HK1252322A1 (zh) 2019-05-24
RU2746322C2 (ru) 2021-04-12
ES2820358T3 (es) 2021-04-20
JP2018522018A (ja) 2018-08-09
AU2023202221A1 (en) 2023-05-04
IL305989A (en) 2023-11-01
AU2016297608B2 (en) 2021-02-18
US11420982B2 (en) 2022-08-23
RU2018105756A3 (el) 2019-12-23
JP6858745B2 (ja) 2021-04-14
EP4286387A2 (en) 2023-12-06
RS60840B1 (sr) 2020-10-30
EP4286387A3 (en) 2024-02-21
CN108026103A (zh) 2018-05-11
AU2016297608A1 (en) 2018-02-08
US20210171546A1 (en) 2021-06-10
KR102659706B1 (ko) 2024-04-23
WO2017015496A1 (en) 2017-01-26
CA2991326A1 (en) 2017-01-26
JP6995178B2 (ja) 2022-02-21
EP3653628B1 (en) 2022-09-14
EP3325485A1 (en) 2018-05-30
US20190010169A1 (en) 2019-01-10
RU2018105756A (ru) 2019-08-21
US20230257400A1 (en) 2023-08-17
AU2016297087A1 (en) 2018-02-08
KR20180038460A (ko) 2018-04-16
CN108290895A (zh) 2018-07-17
RU2018105609A (ru) 2019-08-26
CA2991305A1 (en) 2017-01-26
IL283355B (en) 2022-08-01
IL276631B (en) 2021-10-31
IL256860B (en) 2020-08-31
SG10202106529XA (en) 2021-07-29
LT3325483T (lt) 2020-01-27
US20190112320A1 (en) 2019-04-18
IL256854A (en) 2018-03-29
US20180201626A1 (en) 2018-07-19
JP2018524387A (ja) 2018-08-30
JP2023162264A (ja) 2023-11-08
US20170051011A1 (en) 2017-02-23
SI3325482T1 (sl) 2020-11-30
US10081640B2 (en) 2018-09-25
HK1252323A1 (zh) 2019-05-24
CN108290895B (zh) 2021-03-19
CN108055844A (zh) 2018-05-18
PL3325483T3 (pl) 2020-05-18
KR102660070B1 (ko) 2024-04-24
IL294651A (en) 2022-09-01
AU2021202403A1 (en) 2021-05-20
US10899775B2 (en) 2021-01-26
IL294651B2 (en) 2024-02-01
JP2018526340A (ja) 2018-09-13
EP3325482B1 (en) 2020-06-24
SI3325483T1 (sl) 2020-03-31
EP3325485B1 (en) 2020-04-08
EP3325482A1 (en) 2018-05-30
US20170050985A1 (en) 2017-02-23
RU2018105752A3 (el) 2019-12-30
WO2017015502A8 (en) 2017-03-02
HRP20201479T1 (hr) 2020-12-11
IL283355A (en) 2021-07-29
US10392407B2 (en) 2019-08-27
IL286788B1 (en) 2023-09-01
RU2018105609A3 (el) 2020-04-30
CA2991305C (en) 2024-03-12
LT3325482T (lt) 2020-11-25
US10787463B2 (en) 2020-09-29
PL3325482T3 (pl) 2021-01-11
JP2021035958A (ja) 2021-03-04
RU2727151C2 (ru) 2020-07-21
CN113087763A (zh) 2021-07-09
EP3778602B1 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
CY1122553T1 (el) Μεθοδοι παρασκευης κυτταροτοξικων παραγωγων βενζοδιαζεπινης
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CY1124809T1 (el) Διαστεροεπιλεκτικη συνθεση φωσφορικων παραγωγων και προφαρμακου γεμσιταβινης nuc-1031
MA54254A (fr) Dérivés de benzodiazépine cytotoxique
IL287405A (en) Methods for preparing cytotoxic benzodiazepine derivatives
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2018005354A2 (es) Derivados novedosos de diamino piridina
EP4361128A3 (en) Methods of preparing cytotoxic benzodiazepine derivatives
EP4365173A3 (en) Methods of preparing cytotoxic benzodiazepine derivatives
EA201791596A1 (ru) Пиразоловые соединения
CO7051029A2 (es) Proceso para la preparacion de fenilpropanonas sustituidas